Our Press Releases | Association for Accessible Medicines

AAM All Access Podcast - Dan Leonard speaks with Mary Beth Powers, President and CEO of CMMB.

IGBA Global Biosimilars Week: Strengthening Healthcare – The Value of Biosimilar Medicines. November 11-18, 2022.

Nov 14, 2022 | Susan Reilly

Raising Awareness for Biosimilars for Stakeholders Around the World

Closeup cashless wireless payment with credit card at the pharmacy

Oct 14, 2022 | Susan Reilly

AAM Statement on President Biden's Executive Order on Lowering Prescription Drug Costs

Oct 3, 2022 | Susan Reilly

AAM Statement on the Centers for Medicare & Medicaid Services’ Implementation of Medicare Part B Payment Changes for Biosimilars

2022 2022 U.S Generic and Biosimilar Medicines Savings Report

Sep 21, 2022 | Susan Reilly

Generic and Biosimilar Drugs Generate A Record $373 Billion For America’s Patients and Healthcare System in 2021

Avalere: New Analysis of Trends in Part D Generic Tiering, Pricing, and Patient Spending

Sep 15, 2022 | Susan Reilly

AAM Statement: New Study Shows Formulary Abuses Force Patients to Pay More for Generic Drugs Even as the Prices of Those Drugs Go Down

Capitol Building - Washington D.C.

Aug 7, 2022 | Allen Goldberg

AAM Statement on Senate Passage of Inflation Reduction Act

David Gaugh at GRx+Biosims (North Bethesda, Maryland)

Jul 28, 2022 | Allen Goldberg

Association for Accessible Medicines (AAM) Elevates David Gaugh to Executive Vice President for Sciences & Regulatory Affairs

Misguided Drug Pricing Reform

Jul 6, 2022 | Allen Goldberg

AAM Statement on BBB 2.0

Drug manufacture

Jun 6, 2022 | Allen Goldberg

Giuseppe Randazzo Joins AAM as Vice President, Sciences and Regulatory Affairs

Ariel with Medicines

May 23, 2022 | Allen Goldberg

AAM Statement in Response to Federal Trade Commission Request for Information on PBM Business Practices

May 16, 2022 | Allen Goldberg

Association for Accessible Medicines Names Craig Burton as Senior Vice President, Policy & Strategic Alliances, and Executive Director of the Biosimilars Council

Headquarter of the U.S. Food and Drug Administration (FDA)

May 11, 2022 | Allen Goldberg

AAM Statement on House Energy and Commerce Health Subcommittee Markup of H.R. 7667 Reauthorizing Generic Drug and Biosimilar User Fee Amendments